Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone and melatonin combination therapy for treatment-resistant major depressive disorder
IRCT201505271743N13Phase 4Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of buspirone and melatonin in major depressive disorder (MDD) and treatment-resistant depression (TRD), sponsored by Hamadan University of Medical Sciences. Started Aug 2015; status: completed.
02
Drugs
buspironemelatonin
03
Conditions
major depressive disorder (MDD)treatment-resistant depression (TRD)
Beyond the preview
Go deeper on IRCT201505271743N13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201505271743N13.